These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 34921523)

  • 1. Safety and tolerability of combination therapy with ambrisentan and tadalafil for the treatment of pulmonary arterial hypertension in children: Real-world experience.
    Issapour A; Frank B; Crook S; Hite MD; Dorn ML; Rosenzweig EB; Ivy DD; Krishnan US
    Pediatr Pulmonol; 2022 Mar; 57(3):724-733. PubMed ID: 34921523
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and hemodynamic improvements after adding ambrisentan to background PDE5i therapy in patients with pulmonary arterial hypertension exhibiting a suboptimal therapeutic response (ATHENA-1).
    Shapiro S; Torres F; Feldman J; Keogh A; Allard M; Blair C; Gillies H; Tislow J; Oudiz RJ
    Respir Med; 2017 May; 126():84-92. PubMed ID: 28427554
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Initial tadalafil and ambrisentan combination therapy in pulmonary arterial hypertension: cLinical and haemodYnamic long-term efficacy (ITALY study).
    D'Alto M; Romeo E; Argiento P; Paciocco G; Prediletto R; Ghio S; Correale M; Lo Giudice F; Badagliacca R; Greco A; Vizza CD
    J Cardiovasc Med (Hagerstown); 2018 Jan; 19(1):12-17. PubMed ID: 29215546
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial.
    Coghlan JG; Galiè N; Barberà JA; Frost AE; Ghofrani HA; Hoeper MM; Kuwana M; McLaughlin VV; Peacock AJ; Simonneau G; Vachiéry JL; Blair C; Gillies H; Miller KL; Harris JHN; Langley J; Rubin LJ;
    Ann Rheum Dis; 2017 Jul; 76(7):1219-1227. PubMed ID: 28039187
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of newly diagnosed sarcoid-associated pulmonary hypertension with ambrisentan and tadalafil combination therapy.
    Abston E; Hon S; Lawrence R; Berman J; Govender P; Farber HW
    Sarcoidosis Vasc Diffuse Lung Dis; 2020; 37(2):234-238. PubMed ID: 33093789
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension.
    Galiè N; Barberà JA; Frost AE; Ghofrani HA; Hoeper MM; McLaughlin VV; Peacock AJ; Simonneau G; Vachiery JL; Grünig E; Oudiz RJ; Vonk-Noordegraaf A; White RJ; Blair C; Gillies H; Miller KL; Harris JH; Langley J; Rubin LJ;
    N Engl J Med; 2015 Aug; 373(9):834-44. PubMed ID: 26308684
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ambrisentan: a review of its use in pulmonary arterial hypertension.
    Rivera-Lebron BN; Risbano MG
    Ther Adv Respir Dis; 2017 Jun; 11(6):233-244. PubMed ID: 28425346
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual phosphodiesterase type 5 inhibitor therapy for refractory pulmonary arterial hypertension: a pilot study.
    Kimura M; Tamura Y; Takei M; Yamamoto T; Ono T; Fujita J; Kataoka M; Kuwana M; Satoh T; Fukuda K
    BMC Pulm Med; 2015 May; 15():62. PubMed ID: 25971443
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical safety, pharmacokinetics, and efficacy of ambrisentan therapy in children with pulmonary arterial hypertension.
    Takatsuki S; Rosenzweig EB; Zuckerman W; Brady D; Calderbank M; Ivy DD
    Pediatr Pulmonol; 2013 Jan; 48(1):27-34. PubMed ID: 22511577
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term safety and tolerability of ambrisentan treatment for pediatric patients with pulmonary arterial hypertension: An open-label extension study.
    Ivy D; Beghetti M; Juaneda-Simian E; Ravindranath R; Lukas MA; Machlitt-Northen S; Scott N; Narita J; Berger RMF
    Eur J Pediatr; 2024 May; 183(5):2141-2153. PubMed ID: 38366267
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized study of adding tadalafil to existing ambrisentan in pulmonary arterial hypertension.
    Zhuang Y; Jiang B; Gao H; Zhao W
    Hypertens Res; 2014 Jun; 37(6):507-12. PubMed ID: 24646647
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Efficacy and safety of endothelin receptor antagonists combined with phosphodiesterase 5 inhibitor in the treatment of pulmonary arterial hypertension: a network meta-analysis].
    Fu WH; Chen PL; Xia JL; Fu L; Shen Y; He WJ; Chen YH; Ren N; Jiang Q; Ma R; Wang T; Wang XN; Zhang NF; Liu CL
    Zhonghua Jie He He Hu Xi Za Zhi; 2022 Feb; 45(2):158-170. PubMed ID: 35135085
    [No Abstract]   [Full Text] [Related]  

  • 13. Ambrisentan and Tadalafil Up-front Combination Therapy in Scleroderma-associated Pulmonary Arterial Hypertension.
    Hassoun PM; Zamanian RT; Damico R; Lechtzin N; Khair R; Kolb TM; Tedford RJ; Hulme OL; Housten T; Pisanello C; Sato T; Pullins EH; Corona-Villalobos CP; Zimmerman SL; Gashouta MA; Minai OA; Torres F; Girgis RE; Chin K; Mathai SC
    Am J Respir Crit Care Med; 2015 Nov; 192(9):1102-10. PubMed ID: 26360334
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Initial combination therapy with ambrisentan and tadalafil and mortality in patients with pulmonary arterial hypertension: a secondary analysis of the results from the randomised, controlled AMBITION study.
    Hoeper MM; McLaughlin VV; Barberá JA; Frost AE; Ghofrani HA; Peacock AJ; Simonneau G; Rosenkranz S; Oudiz RJ; White RJ; Miller KL; Langley J; Harris JHN; Blair C; Rubin LJ; Vachiery JL
    Lancet Respir Med; 2016 Nov; 4(11):894-901. PubMed ID: 27745818
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk Reduction and Right Heart Reverse Remodeling by Upfront Triple Combination Therapy in Pulmonary Arterial Hypertension.
    D'Alto M; Badagliacca R; Argiento P; Romeo E; Farro A; Papa S; Sarubbi B; Russo MG; Vizza CD; Golino P; Naeije R
    Chest; 2020 Feb; 157(2):376-383. PubMed ID: 31563498
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hemodynamics and risk assessment 2 years after the initiation of upfront ambrisentan‒tadalafil in pulmonary arterial hypertension.
    D'Alto M; Badagliacca R; Lo Giudice F; Argiento P; Casu G; Corda M; Correale M; Ghio S; Greco A; Lattanzio M; Mercurio V; Paciocco G; Papa S; Prediletto R; Romeo E; Russo MG; Tayar A; Vitulo P; Vizza CD; Golino P; Naeije R
    J Heart Lung Transplant; 2020 Dec; 39(12):1389-1397. PubMed ID: 32933828
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Macitentan and Tadalafil Combination Therapy in Incident and Prevalent Pulmonary Arterial Hypertension: Real-World Evidence from the OPUS/OrPHeUS Studies.
    Chin KM; Channick R; Kim NH; MacDonald G; Ong R; Martin N; Senatore A; McLaughlin VV
    Adv Ther; 2024 Nov; 41(11):4205-4227. PubMed ID: 39316293
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ambrisentan in portopulmonary hypertension: A multicenter, open-label trial.
    Preston IR; Burger CD; Bartolome S; Safdar Z; Krowka M; Sood N; Ford HJ; Battarjee WF; Chakinala MM; Gomberg-Maitland M; Hill NS
    J Heart Lung Transplant; 2020 May; 39(5):464-472. PubMed ID: 32008947
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma Drug Concentrations in Patients with Pulmonary Arterial Hypertension on Combination Treatment.
    Grünig E; Ohnesorge J; Benjamin N; Burhenne J; Enderle Y; Egenlauf B; Fischer C; Harutyunova S; Huppertz A; Klose H; Haefeli WE
    Respiration; 2017; 94(1):26-37. PubMed ID: 28494463
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Initial combination therapy with ambrisentan + tadalafil on pulmonary arterial hypertension‒related hospitalization in the AMBITION trial.
    Vachiéry JL; Galiè N; Barberá JA; Frost AE; Ghofrani HA; Hoeper MM; McLaughlin VV; Peacock AJ; Simonneau G; Blair C; Miller KL; Langley J; Rubin LJ;
    J Heart Lung Transplant; 2019 Feb; 38(2):194-202. PubMed ID: 30522722
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.